Coeptis Therapeutics Inc (COEP) - Total Assets
Based on the latest financial reports, Coeptis Therapeutics Inc (COEP) holds total assets worth $16.28 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Coeptis Therapeutics Inc - Total Assets Trend (2004–2024)
This chart illustrates how Coeptis Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Coeptis Therapeutics Inc (COEP) market capitalisation for the company's overall valuation and market capitalisation.
Coeptis Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Coeptis Therapeutics Inc's total assets of $16.28 Million consist of 11.8% current assets and 88.2% non-current assets. Review debt load of Coeptis Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.0% |
| Accounts Receivable | $38.98K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $541.88K | 6.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Coeptis Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Coeptis Therapeutics Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Coeptis Therapeutics Inc's current assets represent 11.8% of total assets in 2024, an increase from 0.8% in 2004.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2024, up from 0.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 99.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 6.1% of total assets.
Coeptis Therapeutics Inc Competitors by Total Assets
Key competitors of Coeptis Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Coeptis Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 0.40 | 191.80 |
| Quick Ratio | 2.21 | 0.40 | 191.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.29 Million | $-2.08 Million | $954.00K |
Coeptis Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Coeptis Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.60 |
| Latest Market Cap to Assets Ratio | 7.66 |
| Asset Growth Rate (YoY) | 12.5% |
| Total Assets | $8.91 Million |
| Market Capitalization | $68.21 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Coeptis Therapeutics Inc's assets at a significant premium (7.66x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Coeptis Therapeutics Inc's assets grew by 12.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Coeptis Therapeutics Inc (2004–2024)
The table below shows the annual total assets of Coeptis Therapeutics Inc from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.91 Million | +12.54% |
| 2023-12-31 | $7.92 Million | 0.00% |
| 2022-12-31 | $7.92 Million | +17.00% |
| 2021-12-31 | $6.77 Million | +2151.56% |
| 2020-12-31 | $300.48K | +75.16% |
| 2019-12-31 | $171.54K | +114.43% |
| 2018-12-31 | $80.00K | -47.90% |
| 2005-12-31 | $153.56K | +227.27% |
| 2004-12-31 | $46.92K | -- |
About Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more